Qatar
Sidra launches open science publishing programme
Sidra launches open science publishing programme
The programme, led by Sidra’s Research team, will use the groundbreaking F1000Research platform as an open science publishing venue for Sidra researchers. F1000Reserach is a publishing platform that offers immediate publication and transparent peer review of scientific research. The platform aims to avoid editorial bias by ensuring the inclusion of all source data. The process helps scientists to avoid the traditional, anonymous, pre-publication peer-review process that can cause long delays before new results become visible. The Sidra Medical and Research Center Gateway - http://f1000research.com/channels/sidra - publishes academic articles, data and presentations by its research staff, with a particular focus on pregnancy, cancer immunogenomics (treatment of cancer using genomic immunotherapy), and transcriptomics (the study of the subset of transcribed genes in specific organisms). All articles and associated data are published immediately followed by open invited peer review, in line with F1000Research’s publishing model. Dr Ena Wang, acting chief research officer of Sidra Medical and Research Center, said: “Sidra aspires to set high standards in patient care for the women and children of Qatar through its advanced research programs. We are committed to furthering the scientific understanding of major diseases that have a local and global impact. Big data generation and data sharing are key characteristics of a strong modern research facility like Sidra. It is a driving force for scientific discovery and the implementation of precision medicine.”Under current publication models, it can take months and sometimes years for the description of novel findings or research to see the light of day. By adopting the F1000Research publishing platform, Sidra has cemented its commitment to move the discovery process forward at a faster pace, without making any concession to the quality of its research. This will also allow for discoveries that are being translated into applications to reach patients in Qatar as well as the rest of the world sooner, according to a statement.